Danaher Corporation (DHR)

Sector: Healthcare|Industry: Diagnostics & Research|Market Cap: $169.37B|Employees: 63K


Danaher Corporation is a global science and technology innovator focused on improving human health. The company operates through three segments: Biotechnology, Life Sciences, and Diagnostics, offering a wide range of products and services. Danaher's competitive advantage lies in its recurring revenue model, direct sales approach, and the application of the Danaher Business System (DBS). They have a significant geographic presence with facilities in over 50 countries.

  1. Filings

Filing Highlights

Financial Performance

Consolidated revenues were flat year-over-year, with core sales declining driven by the Biotechnology and Life Sciences segments, partially offset by growth in Diagnostics. This indicates potential challenges in specific markets or product lines.

Net earnings attributable to common stockholders decreased from $4.7 billion in 2023 to $3.9 billion in 2024, driven by intangible asset impairments and increased operating expenses. This suggests cost management efforts were insufficient to offset negative factors.

Operating cash flow increased 3% YoY, primarily due to improvements in trade accounts receivable, inventories, and trade accounts payable. This indicates improved efficiency in working capital management.

Growth & Strategy

Management Execution

Risk Factors

Competitive Position

Operational Efficiency

Innovation & Technology

Capital Allocation

ESG Initiatives

Market Environment